CN103073485A - Preparation method for clevidipine butyrate - Google Patents
Preparation method for clevidipine butyrate Download PDFInfo
- Publication number
- CN103073485A CN103073485A CN2013100180122A CN201310018012A CN103073485A CN 103073485 A CN103073485 A CN 103073485A CN 2013100180122 A CN2013100180122 A CN 2013100180122A CN 201310018012 A CN201310018012 A CN 201310018012A CN 103073485 A CN103073485 A CN 103073485A
- Authority
- CN
- China
- Prior art keywords
- carboxylic acid
- methyl
- preparation
- dihydropyridine
- dichlorophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- XRKOOHTZZDPJNE-UHFFFAOYSA-N CCCCCC(F)(F)F Chemical compound CCCCCC(F)(F)F XRKOOHTZZDPJNE-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
The invention discloses a preparation method for clevidipine butyrate. The preparation method comprises the steps as follows: hydrogenating 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3-carboxy methyl-5-aromatic ring substituted methyl carboxylate to prepare 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3-carboxy methyl-5-carboxy, and reacting with chloromethyl butyrate to prepare clevidipine butyrate. The preparation method is easy for acquisition of raw materials, moderate in reaction conditions, simple and convenient to operate and low in cost, and is suitable for industrial production.
Description
Technical field
The invention belongs to the pharmaceutical chemistry technical field, more particularly, relate to the preparation method of a kind of novel antihypertensive medicament butyrate clevidipine (Clevidipine Butyrate).
Background technology
Hypertension critical illness and perioperative hypertension all are common and very harmful to patient diseases, adopt intravenous injection depressor that it is treated and can control fast blood pressure, thereby reduce the generation of various complication.Butyrate clevidipine is a kind of intravenous injection dihydropyridine calcium channel antagonist, also is the first used for intravenous injection antihypertensive drug that U.S. FDA was ratified over past ten years simultaneously.Its onset is rapid, action time is short, be easy to regulation and control, few side effects, carry out metabolism in blood and tissue, thereby is very good used for intravenous injection antihypertensive drug, will be the important selection of emergency room, Operation theatre and intensive care unit patient controlling of blood pressure.
The synthetic method that relates to the butyrate clevidipine bulk drug mainly contains following patent and article: WO2000/31035, WO1995/12578, CN101759631A, " Chinese Journal of Pharmaceuticals ", 2009,40(10), 791, " Chinese Journal of Pharmaceuticals " 2010,41 (3), 170, " Chinese Journal of Pharmaceuticals " 2011,42(7), 484, " modern medicines and clinical " 2011,26(1), 40, Chem.Pharm, Bull.1994,42,1579, Chem.Pharm, Bull.1993,41,1049, Chem.Pharm, Bull.1993,41,108.The synthetic method of report respectively has its relative merits.
Patent WO1995/12578 has reported the synthetic route of many butyrate clevidipines, embodiment has only been introduced from the route of intermediate II by esterification synthetic butyric acid Clevidipine, patent WO1995/13066 has also reported from the intermediate II by esterification synthetic butyric acid Clevidipine, but the response situation synthetic and other synthetic routes of intermediate II are all not mentioned.
Patent WO1995/31035 has reported from 4-(2, the 3-dichlorophenyl)-2,6-dimethyl-Isosorbide-5-Nitrae-dihydropyridine-3-carboxylic acid methyl-5-carboxylic acid propionitrile ester synthetic butyric acid Clevidipine that sets out, but the preparation of not mentioned intermediate VI.
Patent CN101759631A, " Chinese Journal of Pharmaceuticals " 2011,42(7), 484, " modern medicines and clinical " 2011,26(1), 40, Chem.Pharm, Bull.1994,42,1579, Chem.Pharm, Bull.1993,41,1049, Chem.Pharm, Bull.1993,41,108 have reported the synthetic of butyrate clevidipine, and this method has been used the more expensive 3-itrile group propyl alcohol of price, and produce a large amount of waste water that contains alcohol during hydrolysis.
" Chinese Journal of Pharmaceuticals " 2010,41 (3), 170 have reported the synthetic route of butyrate clevidipine, but wherein inevitably follow the formation of two hydrolysates in the methyl esters hydrolytic process, so severe reaction conditions, difficult control, and it is large to produce the wastewater flow rate that contains alcohol, is not suitable for large industrial production.
In sum, all adopt 4-(2 in the preparation of butyrate clevidipine, the 3-dichlorophenyl)-2,6-dimethyl-Isosorbide-5-Nitrae-dihydropyridine-3-carboxylic acid methyl-5-carboxylic acid is as its necessary intermediate (hereinafter to be referred as " monocarboxylic acid " intermediate).And " monocarboxylic acid " intermediate that adopts aforesaid method to prepare all inevitably contains impurity 4-(2, the 3-dichlorophenyl)-2,6-dimethyl-Isosorbide-5-Nitrae-dihydro-3,5-pyridine-dicarboxylic acid (hereinafter to be referred as: " dicarboxylic acid " impurity); The existence of " dicarboxylic acid " impurity can be introduced corresponding impurity in butyrate clevidipine, therefore will obtain meeting loaded down with trivial details, the complicated purge process of butyrate clevidipine needs of medicinal requirements.Therefore, be necessary further to improve the preparation method of butyrate clevidipine.
Summary of the invention
The inventor has been surprisingly found out that the preparation method of a kind of butyrate clevidipine and midbody compound thereof through a large amount of experiments, and the butyrate clevidipine purity that obtains by this preparation method is high, and contains hardly " dicarboxylic acid " impurity.
An object of the present invention is to provide the preparation method of butyrate clevidipine midbody compound.
Another object of the present invention provides a kind of preparation method of butyrate clevidipine.
Specifically, the invention provides a kind of butyrate clevidipine midbody compound 4-(2, the 3-dichlorophenyl)-2,6-dimethyl-1, the preparation method of 4-dihydropyridine-3-carboxylic acid methyl-5-carboxylic acid (hereinafter to be referred as " monocarboxylic acid " intermediate) comprises the steps:
(1) 2,3 dichloro benzaldehyde, etheric acid aromatic nucleus are replaced methyl esters, 3-amino-2-butylene acid methyl esters hybrid reaction, obtain 4-(2, the 3-dichlorophenyl)-2,6-dimethyl-Isosorbide-5-Nitrae-dihydropyridine-3-carboxylic acid methyl-5-carboxylic acid aromatic nucleus replaces methyl esters;
(2) with 4-(2, the 3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3-carboxylic acid methyl-5-carboxylic acid aromatic nucleus replaces methyl esters and carries out hydrogenolysis, obtains 4-(2, the 3-dichlorophenyl)-2,6-dimethyl-Isosorbide-5-Nitrae-dihydropyridine-3-carboxylic acid methyl-5-carboxylic acid.
In embodiments of the invention; the preparation method of " monocarboxylic acid " provided by the invention intermediate; wherein; the etheric acid aromatic nucleus replaces methyl esters or 4-(2; the 3-dichlorophenyl)-2; 6-dimethyl-1; it is the phenyl methyl esters that 4-dihydropyridine-3-carboxylic acid methyl-5-carboxylic acid aromatic nucleus replaces the aromatic nucleus replacement methyl esters described in the methyl esters; benzene methyl (as: (p-methoxyl group) benzene methyl that replaces; (p-chloro) benzene methyl; (2; the 4-dichloro-) benzene methyl etc.); the pyridine methyl esters; or the substituted pyridines methyl esters is (such as (2-methyl) pyridine methyl esters; (2; the 5-dimethyl) pyridine methyl esters; (2-ethyl oxygen formyl radical) pyridine methyl esters etc.); preferably, be the phenyl methyl esters.
In embodiments of the invention, the preparation method of " monocarboxylic acid " provided by the invention intermediate, wherein, described hydrogenolysis carries out in organic solvent, preferably, carries out in methyl alcohol or ethanol.
In embodiments of the invention, the preparation method of " monocarboxylic acid " provided by the invention intermediate, wherein, described hydrogenolysis temperature is 0-30 ℃; Preferred temperature is 20-25 ℃.
In embodiments of the invention, the preparation method of " monocarboxylic acid " provided by the invention intermediate, wherein, the reaction times of described hydrogenolysis is 2-40 hour.
In embodiments of the invention, the preparation method of " monocarboxylic acid " provided by the invention intermediate, wherein, described hydrogenolysis is to carry out existing under the condition of catalyzer; Here, described catalyzer is palladium carbon, platinum, platinum oxide or Raney's nickel etc., preferably, is palladium carbon.
In embodiments of the invention, the preparation method of " monocarboxylic acid " provided by the invention intermediate, wherein, described hydrogenolysis is to carry out under the condition of pressurization, preferably, pressure is 0.5-5atm.More preferably pressure is 1-1.2atm.
In the preferred embodiment of the invention, the invention provides a kind of butyrate clevidipine midbody compound 4-(2, the 3-dichlorophenyl)-2, the preparation method of 6-dimethyl-Isosorbide-5-Nitrae-dihydropyridine-3-carboxylic acid methyl-5-carboxylic acid comprises the steps:
(1) with 2,3 dichloro benzaldehyde, etheric acid benzene methyl, 3-amino-2-butylene acid methyl esters hybrid reaction, obtain 4-(2, the 3-dichlorophenyl)-2,6-dimethyl-Isosorbide-5-Nitrae-dihydropyridine-3-carboxylic acid methyl-5-carboxylic acid benzene methyl;
(2) with 4-(2, the 3-dichlorophenyl)-2,6-dimethyl-Isosorbide-5-Nitrae-dihydropyridine-3-carboxylic acid methyl-5-carboxylic acid benzene methyl obtains 4-(2, the 3-dichlorophenyl carrying out hydrogenolysis)-2,6-dimethyl-Isosorbide-5-Nitrae-dihydropyridine-3-carboxylic acid methyl-5-carboxylic acid;
Wherein, described hydrogenolysis carries out in organic solvent, preferably, carries out in methyl alcohol or ethanol;
Described hydrogenolysis temperature is 0-30 ℃; Preferred temperature is 20-25 ℃.
The reaction times of described hydrogenolysis is 2-40 hour.
Described hydrogenolysis is to carry out existing under the condition of catalyzer; Here, described catalyzer is palladium carbon, platinum, platinum oxide or Raney's nickel etc., preferably, is palladium carbon.
Described hydrogenolysis is to carry out under the condition of pressurization, and preferably, pressure is 0.5-5atm.More preferably pressure is 1-1.2atm.
In embodiments of the invention, described etheric acid aromatic nucleus replacement methyl esters majority has commercially available, and it is standby also can to replace Methanol by ketene dimer and aromatic nucleus, and related raw material is cheap and easy to get.For example, the etheric acid benzene methyl has commercially available, also can be reacted by phenylethyl alcohol and ketene dimer to obtain (reference: Chinese journal ofpharmaceuticals2011,42(7) in the presence of triethylamine in tetrahydrofuran solution: 484-486).
On the other hand, the invention provides the preparation method of butyrate clevidipine, comprising:
I) 4-(2, the 3-dichlorophenyl)-2, the preparation of 6-dimethyl-Isosorbide-5-Nitrae-dihydropyridine-3-carboxylic acid methyl-5-carboxylic acid;
Ii) 4-(2, the 3-dichlorophenyl)-2,6-dimethyl-Isosorbide-5-Nitrae-dihydropyridine-3-carboxylic acid methyl-5-carboxylic acid and the reaction of butanic acid chloromethyl ester obtain butyrate clevidipine;
Here, described 4-(2,3-dichlorophenyl)-2, the preparation of 6-dimethyl-Isosorbide-5-Nitrae-dihydropyridine-3-carboxylic acid methyl-5-carboxylic acid comprises the following steps:
(1) 2,3 dichloro benzaldehyde, etheric acid aromatic nucleus are replaced methyl esters, 3-amino-2-butylene acid methyl esters hybrid reaction, obtain 4-(2, the 3-dichlorophenyl)-2,6-dimethyl-Isosorbide-5-Nitrae-dihydropyridine-3-carboxylic acid methyl-5-carboxylic acid aromatic nucleus replaces methyl esters;
(2) with 4-(2, the 3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3-carboxylic acid methyl-5-carboxylic acid aromatic nucleus replaces methyl esters and carries out hydrogenolysis, obtains 4-(2, the 3-dichlorophenyl)-2,6-dimethyl-Isosorbide-5-Nitrae-dihydropyridine-3-carboxylic acid methyl-5-carboxylic acid.
In embodiments of the invention; the preparation method of butyrate clevidipine provided by the invention; wherein; the etheric acid aromatic nucleus replaces methyl esters or 4-(2; the 3-dichlorophenyl)-2; 6-dimethyl-1; it is the phenyl methyl esters that 4-dihydropyridine-3-carboxylic acid methyl-5-carboxylic acid aromatic nucleus replaces the aromatic nucleus replacement methyl esters described in the methyl esters; benzene methyl (as: (p-methoxyl group) benzene methyl that replaces; (p-chloro) benzene methyl; (2; the 4-dichloro-) benzene methyl etc.); the pyridine methyl esters; or the substituted pyridines methyl esters is (such as (2-methyl) pyridine methyl esters; (2; the 5-dimethyl) pyridine methyl esters; (2-ethyl oxygen formyl radical) pyridine methyl esters etc.); preferably, be the phenyl methyl esters.
In embodiments of the invention, the preparation method of butyrate clevidipine provided by the invention, wherein, described hydrogenolysis carries out in organic solvent, preferably, carries out in methyl alcohol or ethanol.
In embodiments of the invention, the preparation method of butyrate clevidipine provided by the invention, wherein, described hydrogenolysis temperature is 0-30 ℃; Preferred temperature is 20-25 ℃.
In embodiments of the invention, the preparation method of butyrate clevidipine provided by the invention, wherein, the reaction times of described hydrogenolysis is 2-40 hour.
In embodiments of the invention, the preparation method of butyrate clevidipine provided by the invention, wherein, described hydrogenolysis is to carry out existing under the condition of catalyzer; Here, described catalyzer is palladium carbon, platinum, platinum oxide or Raney's nickel etc., preferably, is palladium carbon.
In embodiments of the invention, the preparation method of butyrate clevidipine provided by the invention, wherein, described hydrogenolysis is to carry out under the condition of pressurization, preferably, pressure is 0.5-5atm.More preferably pressure is 1-1.2atm.
In the preferred embodiment of the invention, the invention provides a kind of preparation method of butyrate clevidipine, comprising:
I) 4-(2, the 3-dichlorophenyl)-2, the preparation of 6-dimethyl-Isosorbide-5-Nitrae-dihydropyridine-3-carboxylic acid methyl-5-carboxylic acid;
Ii) 4-(2, the 3-dichlorophenyl)-2,6-dimethyl-Isosorbide-5-Nitrae-dihydropyridine-3-carboxylic acid methyl-5-carboxylic acid and the reaction of butanic acid chloromethyl ester obtain butyrate clevidipine;
Here, described 4-(2,3-dichlorophenyl)-2, the preparation of 6-dimethyl-Isosorbide-5-Nitrae-dihydropyridine-3-carboxylic acid methyl-5-carboxylic acid comprises the following steps:
(1) with 2,3 dichloro benzaldehyde, etheric acid benzene methyl, 3-amino-2-butylene acid methyl esters hybrid reaction, obtain 4-(2, the 3-dichlorophenyl)-2,6-dimethyl-Isosorbide-5-Nitrae-dihydropyridine-3-carboxylic acid methyl-5-carboxylic acid benzene methyl;
(2) with 4-(2, the 3-dichlorophenyl)-2,6-dimethyl-Isosorbide-5-Nitrae-dihydropyridine-3-carboxylic acid methyl-5-carboxylic acid benzene methyl carries out hydrogenolysis, obtains 4-(2, the 3-dichlorophenyl)-2,6-dimethyl-Isosorbide-5-Nitrae-dihydropyridine-3-carboxylic acid methyl-5-carboxylic acid;
Here, described hydrogenolysis carries out in organic solvent, preferably, carries out in methyl alcohol or ethanol;
Described hydrogenolysis temperature is 0-30 ℃; Preferred temperature is 20-25 ℃.
The reaction times of described hydrogenolysis is 2-40 hour.
Described hydrogenolysis is to carry out existing under the condition of catalyzer; Here, described catalyzer is palladium carbon, platinum, platinum oxide or Raney's nickel etc., preferably, is palladium carbon.
Described hydrogenolysis is to carry out under the condition of pressurization, and preferably, pressure is 0.5-5atm.More preferably pressure is 1-1.2atm.
Generally, the aromatic nucleus of " monocarboxylic acid " intermediate replaces methyl esters can further react generation 4-(2,3-dichlorophenyl in hydrogenolysis process)-lupetidine-3-carboxylate methyl ester-5-carboxylic acid, be difficult to obtain " monocarboxylic acid " intermediate; The inventor is unexpected in the impurity of preparation butyrate clevidipine to find that by avoiding Isosorbide-5-Nitrae-dihydropyridine ring to be converted into phenyl ring in hydrogenolysis condition of the present invention, accident obtains " monocarboxylic acid " intermediate of high yield.Further research finds to adopt present method preparation " monocarboxylic acid " midbody product purity high, during for the preparation of the bulk drug butyrate clevidipine, can greatly simplify last handling process, reduce production costs.
Compared with prior art, the present invention has following features.
1. raw material etheric acid aromatic nucleus replaces methyl esters (for example benzene methyl) and can replace methyl alcohol (for example phenylcarbinol) preparation by ketene dimer and aromatic nucleus, and related raw material is cheap and easy to get.
2. hydrogenolysis can replace aromatic nucleus that methyl esters dissociates fully and methoxycarbonyl is unaffected, can be contained hardly high purity " monocarboxylic acid " intermediate of " dicarboxylic acid " impurity.
3. adopt the method for hydrogenolysis, avoided containing pure waste water, clean environment firendly by what alkaline hydrolysis produced.
4. " monocarboxylic acid " intermediate that adopts this law to prepare prepares the butyrate clevidipine as bulk drug, and purge process is simple and easy to do, and yield obviously improves, and production cost significantly reduces.
Description of drawings
What Fig. 1 represented is the HPLC collection of illustrative plates of the embodiment of the invention.
What Fig. 2 represented is the HPLC collection of illustrative plates of the butyrate clevidipine of Comparative Examples preparation.
Embodiment
Be described in detail the present invention with the following examples, but it not limitation of the present invention.
The test condition of NMR is: with DMSO-d
6Or CDCl
3For solvent, TMS are interior mapping examination; Testing tool is AVANCE DRX500M nuclear magnetic resonance spectrometer.
The HPLC test condition is: take C18 silane group silica gel as weighting agent; With methyl alcohol/acetonitrile/water (40:40:20) wash-out; The detection wavelength is 246nm.
Embodiment 1:4-(2,3-dichlorophenyl)-2,6-dimethyl-Isosorbide-5-Nitrae-dihydropyridine-3-carboxylic acid methyl-5-carboxylic acid synthetic
Step 1: etheric acid benzene methyl synthetic
With benzylalcohol 27g(0.15mol), the triethylamine (1.8g) of catalytic amount is dissolved in the 100ml tetrahydrofuran (THF), and solution is heated to boiling.In solution, drip ketene dimer 22g(0.26mol under the return stirring), after being added dropwise to complete, the return stirring reaction is 3 hours again.Add 10% citric acid solution 200ml after reaction finishes, stirred 10 minutes.Layering, the water layer chloroform extraction of 100ml * 3.Combining extraction liquid is successively with the water of 80ml * 3, the saturated common salt water washing of 100ml * 2.Add an amount of anhydrous sodium sulphate, stirring at room 2 hours.Behind the filtering siccative, filtrate decompression concentrates to get yellow oil.Do not add purifying, be directly used in the next step.
Step 2:4-(2,3-dichlorophenyl)-2,6-dimethyl-Isosorbide-5-Nitrae-dihydropyridine-3-carboxylic acid methyl-5-carboxylic acid benzene methyl synthetic
With 2,3 dichloro benzaldehyde 24.4g(0.14mol), the about 0.15mol of upper step reaction gained etheric acid benzene methyl crude product 28.8g(), 3-amino-2-butylene acid methyl esters 16.1g(0.14mol) join in the 200ml methyl alcohol, stirring makes material dissolution.About 5 hours of heating reflux reaction.After reaction finishes, the underpressure distillation desolventizing.That the gained resistates does not add is refining, be directly used in the next step.
Step 3:4-(2,3-dichlorophenyl)-2,6-dimethyl-Isosorbide-5-Nitrae-dihydropyridine-3-carboxylic acid methyl-5-carboxylic acid synthetic
Add 4-(2 in the hydrogenation still, the 3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3-carboxylic acid methyl-5-carboxylic acid benzene methyl crude product (44.6g, 0.1mol), methyl alcohol 300ml, 10% palladium carbon 2g passes into hydrogen under 20 ℃, and pressure is 1atm, to not absorbing till the hydrogen, filter, use methyl alcohol drip washing, merging filtrate is concentrated into about 100ml, cooling, filter, get the 23.9g faint yellow solid, productive rate 67%.
1H?NMR(DMSO-d
6，ppm):δ=11.62（s，1H）,8.81(s,1H)，7.38-7.21(m，3H)，5.29（s，1H），3.48（s，3H）、2.22（s，3H）、2.21（s，3H）。
Embodiment 2:4-(2,3-dichlorophenyl)-2,6-dimethyl-Isosorbide-5-Nitrae-dihydropyridine-3-carboxylic acid methyl-5-carboxylic acid synthetic
With 4-(2,3-dichlorophenyl)-2,6-dimethyl-Isosorbide-5-Nitrae-dihydropyridine-3-carboxylic acid methyl-5-carboxylic acid-(p-methyl) benzene methyl is raw material according to the method preparation similar to embodiment 1, and yield is 63%.
Embodiment 3: butyrate clevidipine synthetic
In the there-necked flask, add 4-(2, the 3-dichlorophenyl)-2,6-dimethyl-Isosorbide-5-Nitrae-dihydropyridine-3-carboxylic acid methyl-5-carboxylic acid 35.6g(0.1mol) (preparation method sees embodiment 1, embodiment 2), saleratus 20g(0.2mol), DMF500ml, stir the lower butanic acid chloromethyl ester 20.5g(0.15mol that adds), again in 60 ℃ of reactions 12 hours, be cooled to room temperature, join in the 3L water, use CH
2Cl
2(1L * 3) extraction, behind the anhydrous sodium sulfate drying, be evaporated to dried, refining with Virahol, get white solid 28.7g, productive rate 63%.
Mp.：136.5℃～138.2℃。HPLC:99.7%; Single contaminant is no more than 0.2%.The HPLC collection of illustrative plates is seen Fig. 1.
1H?NMR(CDCl
3，ppm):δ=7.01~7.27(m,3H)，6.29(s,1H)，5.73(d,1H)，
5.68(d,1H)，5.39(s,1H)，3.48(s,1H)，2.19~2.25(m,8H)，1.55(m,2H)，0.83(t,3H)。
Comparative Examples: butyrate clevidipine synthetic
Step 1: etheric acid (2-cyano ethyl) ester synthesis
With 3-hydroxypropionitrile 10g(0.14mol), the triethylamine (1.8g) of catalytic amount is dissolved in the 100ml tetrahydrofuran (THF), and solution is heated to boiling.In solution, drip ketene dimer 22g(0.26mol under the return stirring), after being added dropwise to complete, the return stirring reaction is 3 hours again.Add 10% citric acid solution 200ml after reaction finishes, stirred 10 minutes.Layering, the water layer dichloromethane extraction of 100ml * 3.Merge organic layer, successively with the water of 100ml * 2, the saturated common salt water washing of 100ml * 2.Add an amount of anhydrous sodium sulphate, stirring at room 2 hours.Behind the filtering siccative, filtrate decompression concentrates to get yellow oil.Do not add purifying, be directly used in the next step.
Step 2:4-(2, the 3-dichlorophenyl)-2,6-dimethyl-Isosorbide-5-Nitrae-dihydropyridine-3-carboxylic acid methyl-5-carboxylic acid (2-cyano ethyl) ester synthesis
With 2,3-dichlorobenzaldehyde 23.5g(0.135mol), the about 0.135mol of upper step reaction gained etheric acid (2-cyano ethyl) ester crude product 21.0g(), 3-amino-2-butylene acid methyl esters 15.5g(0.135mol) join in the 200ml methyl alcohol, stirring makes material dissolution.About 5 hours of heating reflux reaction.After reaction finishes, the underpressure distillation desolventizing.Residuum separates (eluent: ethyl acetate-sherwood oil (1:1)), get faint yellow solid 41.6g, yield 76% through column chromatography.（mp103-105℃）。
Step 3:4-(2,3-dichlorophenyl)-2,6-dimethyl-Isosorbide-5-Nitrae-dihydropyridine-3-carboxylic acid methyl-5-carboxylic acid synthetic
With gained intermediate 41.6g(0.10mol of upper step) be dissolved in the mixing solutions of 240ml methylene dichloride and 120ml the formation of methanol, add sodium sulphite 16.8g(0.22mol), stirring at room 5 hours.Add 200ml after the reaction end, with methylene dichloride 200ml * 3 washings, water layer uses the 3mol/L hcl acidifying to pH3-4 under condition of ice bath, and solid is separated out.Filter and collect the gained solid, be drying to obtain required intermediate, the 28.1g that weighs to get, yield 65%.
Step 4: butyrate clevidipine synthetic
With reference to " embodiment 3 " identical step operation, get butyrate clevidipine, yield 64%.
The HPLC collection of illustrative plates of gained butyrate clevidipine is seen Fig. 2.Test result shows, butyrate clevidipine retention time t
RBe 16.3min, area percentage is 99.6%; At 0.8t
RPlace's impurity peak area reaches 0.24%, has surpassed the limit of quality standard regulation (standard code of butyrate clevidipine is calculated by area normalization method, single related substance must not greater than 0.2%).
Further reached the limit of quality standard regulation with the refining rear related substance of Virahol, refining yield 87%.
Claims (10)
1. butyrate clevidipine midbody compound 4-(2, the 3-dichlorophenyl)-2, the preparation method of 6-dimethyl-Isosorbide-5-Nitrae-dihydropyridine-3-carboxylic acid methyl-5-carboxylic acid comprises the steps:
(1) 2,3 dichloro benzaldehyde, etheric acid aromatic nucleus are replaced methyl esters, 3-amino-2-butylene acid methyl esters hybrid reaction, obtain 4-(2, the 3-dichlorophenyl)-2,6-dimethyl-Isosorbide-5-Nitrae-dihydropyridine-3-carboxylic acid methyl-5-carboxylic acid aromatic nucleus replaces methyl esters;
(2) with 4-(2, the 3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3-carboxylic acid methyl-5-carboxylic acid aromatic nucleus replaces methyl esters and carries out hydrogenolysis, obtains 4-(2, the 3-dichlorophenyl)-2,6-dimethyl-Isosorbide-5-Nitrae-dihydropyridine-3-carboxylic acid methyl-5-carboxylic acid.
2. preparation method according to claim 1, wherein, the etheric acid aromatic nucleus replaces methyl esters or 4-(2, the 3-dichlorophenyl)-2,6-dimethyl-1, it is benzene methyl, pyridine methyl esters or the substituted pyridines methyl esters of phenyl methyl esters, replacement that 4-dihydropyridine-3-carboxylic acid methyl-5-carboxylic acid aromatic nucleus replaces the aromatic nucleus replacement methyl esters described in the methyl esters, preferably, is the phenyl methyl esters.
3. preparation method according to claim 1, wherein, described hydrogenolysis carries out in organic solvent, preferably, carries out in methyl alcohol or ethanol.
4. preparation method according to claim 1, wherein, described hydrogenolysis temperature is 0-30 ℃; Preferred temperature is 20-25 ℃.
5. preparation method according to claim 1, wherein, the reaction times of described hydrogenolysis is 2-40 hour.
6. preparation method according to claim 1, wherein, described hydrogenolysis is to carry out existing under the condition of catalyzer; Described catalyzer is palladium carbon, platinum, platinum oxide or Raney's nickel etc., preferably, is palladium carbon.
7. preparation method according to claim 1, wherein, described hydrogenolysis is to carry out under the condition of pressurization.
8. preparation method according to claim 7, wherein, the condition of described pressurization is that pressure is 0.5-5atm, more preferably pressure is 1-1.2atm.
9. butyrate clevidipine midbody compound 4-(2, the 3-dichlorophenyl)-2, the preparation method of 6-dimethyl-Isosorbide-5-Nitrae-dihydropyridine-3-carboxylic acid methyl-5-carboxylic acid comprises the steps:
(1) with 2,3 dichloro benzaldehyde, etheric acid benzene methyl, 3-amino-2-butylene acid methyl esters hybrid reaction, obtain 4-(2, the 3-dichlorophenyl)-2,6-dimethyl-Isosorbide-5-Nitrae-dihydropyridine-3-carboxylic acid methyl-5-carboxylic acid benzene methyl;
(2) with 4-(2, the 3-dichlorophenyl)-2,6-dimethyl-Isosorbide-5-Nitrae-dihydropyridine-3-carboxylic acid methyl-5-carboxylic acid benzene methyl carries out hydrogenolysis, obtains 4-(2, the 3-dichlorophenyl)-2,6-dimethyl-Isosorbide-5-Nitrae-dihydropyridine-3-carboxylic acid methyl-5-carboxylic acid;
Wherein, described hydrogenolysis carries out in organic solvent, preferably, carries out in methyl alcohol or ethanol;
Described hydrogenolysis temperature is 0-30 ℃; Preferred temperature is 20-25 ℃;
The reaction times of described hydrogenolysis is 2-40 hour;
Described hydrogenolysis is to carry out existing under the condition of catalyzer; Described catalyzer is palladium carbon, platinum, platinum oxide or Raney's nickel etc., preferably, is palladium carbon;
Described hydrogenolysis is to carry out under the condition of pressurization, and preferably, pressure is 0.5-5atm, and more preferably pressure is 1-1.2atm.
10. the preparation method of a butyrate clevidipine comprises:
I) 4-(2, the 3-dichlorophenyl)-2, the preparation of 6-dimethyl-Isosorbide-5-Nitrae-dihydropyridine-3-carboxylic acid methyl-5-carboxylic acid;
Ii) 4-(2, the 3-dichlorophenyl)-2,6-dimethyl-Isosorbide-5-Nitrae-dihydropyridine-3-carboxylic acid methyl-5-carboxylic acid and the reaction of butanic acid chloromethyl ester obtain butyrate clevidipine;
Wherein, 4-(2,3-dichlorophenyl)-2, the preparation of 6-dimethyl-Isosorbide-5-Nitrae-dihydropyridine-3-carboxylic acid methyl-5-carboxylic acid is to adopt the described preparation method of arbitrary claim in the claim 1 to 9.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310018012.2A CN103073485B (en) | 2013-01-17 | 2013-01-17 | A kind of preparation method of butyrate clevidipine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310018012.2A CN103073485B (en) | 2013-01-17 | 2013-01-17 | A kind of preparation method of butyrate clevidipine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103073485A true CN103073485A (en) | 2013-05-01 |
| CN103073485B CN103073485B (en) | 2015-09-02 |
Family
ID=48150206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310018012.2A Active CN103073485B (en) | 2013-01-17 | 2013-01-17 | A kind of preparation method of butyrate clevidipine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103073485B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104597192A (en) * | 2014-12-31 | 2015-05-06 | 武汉科福新药有限责任公司 | Method for detecting clevidipine butyrate and related substances in preparations of clevidipine butyrate |
| CN109721596A (en) * | 2017-10-27 | 2019-05-07 | 广东东阳光药业有限公司 | The dihydropyridine compounds and application thereof that phenyl replaces |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995012578A1 (en) * | 1993-11-05 | 1995-05-11 | Astra Aktiebolag | Short-acting dihydropyridines |
| CN101602710A (en) * | 2009-05-20 | 2009-12-16 | 中国药科大学 | A kind of new preparation method of butyrate clevidipine key intermediate |
| CN101638379A (en) * | 2009-08-21 | 2010-02-03 | 武汉武药科技有限公司 | Preparation method for dihydropyridine type compound |
| CN101759631A (en) * | 2009-12-29 | 2010-06-30 | 中山大学 | Method for preparing butyrate clevidipine |
| CN102001992A (en) * | 2010-10-14 | 2011-04-06 | 清远嘉博制药有限公司 | Method for preparing clevidipine butyrate |
| CN102219728A (en) * | 2010-05-17 | 2011-10-19 | 上海现代制药股份有限公司 | Method for preparing 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-dipicolinic acid monomethyl ester |
-
2013
- 2013-01-17 CN CN201310018012.2A patent/CN103073485B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995012578A1 (en) * | 1993-11-05 | 1995-05-11 | Astra Aktiebolag | Short-acting dihydropyridines |
| CN101602710A (en) * | 2009-05-20 | 2009-12-16 | 中国药科大学 | A kind of new preparation method of butyrate clevidipine key intermediate |
| CN101638379A (en) * | 2009-08-21 | 2010-02-03 | 武汉武药科技有限公司 | Preparation method for dihydropyridine type compound |
| CN101759631A (en) * | 2009-12-29 | 2010-06-30 | 中山大学 | Method for preparing butyrate clevidipine |
| CN102219728A (en) * | 2010-05-17 | 2011-10-19 | 上海现代制药股份有限公司 | Method for preparing 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-dipicolinic acid monomethyl ester |
| CN102001992A (en) * | 2010-10-14 | 2011-04-06 | 清远嘉博制药有限公司 | Method for preparing clevidipine butyrate |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104597192A (en) * | 2014-12-31 | 2015-05-06 | 武汉科福新药有限责任公司 | Method for detecting clevidipine butyrate and related substances in preparations of clevidipine butyrate |
| CN109721596A (en) * | 2017-10-27 | 2019-05-07 | 广东东阳光药业有限公司 | The dihydropyridine compounds and application thereof that phenyl replaces |
| CN109721596B (en) * | 2017-10-27 | 2020-12-18 | 广东东阳光药业有限公司 | Phenyl-substituted dihydropyridines and their use |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103073485B (en) | 2015-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2022222914A1 (en) | Preparation method of l-nicotine | |
| CN101462974A (en) | Process for synthesizing 5-aminovaleric acid hydrochloride | |
| CN102351651A (en) | Preparation method of 3,3,3-trifluoropropanol | |
| CN102485723A (en) | Semi-synthesis of vinpocetine through one kettle way and preparation of water-soluble vinpocetine salt | |
| CN103073485B (en) | A kind of preparation method of butyrate clevidipine | |
| CN113773291A (en) | Improved synthesis method of vitronectin as effective component of cosmetics | |
| CN103804232B (en) | A kind of 1-cyano group-1-(7-methoxyl-3,4-dihydro-1-naphthyl) methanol esters compounds and its preparation method and application | |
| US20140200355A1 (en) | Method for Preparing Optically Pure (-)-Clausenamide Compound | |
| CN108084058A (en) | A kind of preparation method of LCZ696 intermediates | |
| CN105693603A (en) | Improved indacaterol maleate preparation technology | |
| CN101492382A (en) | Novel method for preparing levetiracetam midbody S-(+)-2-aminobutyrate hydrochlorate | |
| CN115322194B (en) | Method for resolving carboxylic acid of non-neridone intermediate | |
| CN102030707A (en) | Method for preparing Blonanserin intermediate | |
| CN105884746B (en) | The synthetic method of fluorine imatinib | |
| CN108658826B (en) | Method for preparing vildagliptin | |
| CN103086956B (en) | A kind of purification process of clevidipine butyrate intermediate | |
| CN102206185B (en) | Process for refining bendazac lysine and analogs thereof | |
| CN105884687A (en) | Preparation method of 5-benzyl benzydamine | |
| CN101723879B (en) | Method for synthesizing (R)-3-ethyl piperidine hydrochloride | |
| CN113754715B (en) | Optical selective process synthesis method of (5R) -5-hydroxyl triptolide | |
| CN103408439A (en) | Chemical synthetic method of norbelladine | |
| CN105732613A (en) | Synthesis method of 9-demethyl-(+)-alpha-dihydrotetrabenazine | |
| CN115504893B (en) | Synthesis method of L-glutamic acid-alpha-tert-butyl ester | |
| CN114874132B (en) | Preparation method of recombinant human receptor protein FKBP12 ligand | |
| CN101381341A (en) | Preparation method of 3-hydroxyl-6-hydroxymethyl pyridine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |